Sign inJoin waitlistJoin the waitlist

Dickran Kazandjian

Clinical Research Lead · University of Miami/Jackson Health System

Credentials: · · ·

History

University of Miami/Jackson Health System
Present
University of Miami/Jackson Health System
Present

U.S. Department of Health and Human Services
2013–2015
Hematology and Medical Oncology
Clinical Center at the National Institutes of Health
2010–2013
Wilford Hall Ambulatory Surgical Center
2006–2009
San Antonio Uniformed Services Health Education Consortium
2003–2006
Boston University School of Medicine
1999–2003

Research

Multiple myeloma epidemiology and survival: A unique malignancy
Review · Seminars in Oncology · 2016 · Sole author · 588 citations
FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy
The Oncologist · 2016 · First of 8 authors · Corresponding · 371 citations
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
JAMA Oncology · 2015 · 267 citations

Ola Landgren
52 papers
NK
Neha Korde
19 papers
Elizabeth Hill
15 papers · 8 as a fellow
FM
Francesco Maura
15 papers
SM
Sham Mailankody
15 papers · 7 as a fellow
GB
Gideon Blumenthal
14 papers
RP
Richard Pazdur
14 papers
Benjamin Diamond
13 papers
AD
Alexander Dew
9 papers
MS
Maryalice Stetler-Stevenson
9 papers
PK
Patricia Keegan
9 papers
David Coffey
8 papers

Clinical trials

Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse
Principal investigator · Recruiting · Phase 2
Dickran Kazandjian, MD
2025–2032
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
Principal investigator · Recruiting · Phase 2
Dickran Kazandjian, MD
2024–2029
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
Principal investigator · Recruiting · Phase 2
University of Miami
2023–2030
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Site PI · Recruiting · Phase 1
K36 Therapeutics, Inc.
2023–2028